References
- McKinnon RA, Cook M, Liauw W, et al. Biosimilarity and interchangeability: principles and evidence: a systematic review. BioDrugs. 2018;32:27–52.
- Nguyen E, Weeda ER, Soberieraj DM, et al. Impact of non-medical switching on clinical and economic outcomes, resource utilization and medication-taking behavior: a systematic literature review. Curr Med Res Opin. 2016;32:1281–1290.
- Cost-motivated treatment changes in Medicare Part B: implications for non-medical switching. The Moran Company; 2016. Arlington, Virginia. [cited 2018 Oct 4]. Available from: http://1yh21u3cjptv3xjder1dco9mx5s.wpengine.netdna-cdn.com/wp-content/uploads/2016/10/Switching-Study-Report-FINAL.pdf.
- Tennessee patient sentiment toward non-medical switching. GHLF CreakyJoints; 2016. Upper Nyack, NY. [cited 2018 Oct 4]. Available from: https://creakyjoints.org/advocacy/tennessee-patient-sentiment-toward-non-medical-drug-switching/.
- Cost-motivated treatment changes in commercial claims: implications for non-medical switching. The Moran Company; 2017. Arlington Virginia. [cited 2018 Oct 4]. Available from: http://1yh21u3cjptv3xjder1dco9mx5s.wpengine.netdna-cdn.com/wp-content/uploads/2013/08/Moran_Commercial-claims-analysis-report_Aug-2017.pdf.
- Wolf D, Skup M, Yang H, et al. Clinical outcomes associated with switching or discontinuation from anti-TNF inhibitors for nonmedical reasons. Clin Ther. 2017;39:849–862.
- Gibofsky A, Skup M, Mittal M, et al. Effects of non-medical switching on outcomes among patients prescribed tumor necrosis factor inhibitors. Curr Med Res Opin. 2017;33:1945–1953.
- Laas K, Peltomaa R, Kautiainen H, et al. Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis. Clin Rheumatol. 2008;27:927–932.
- Jorgensen K, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week randomized, double-blind, non-inferiority trial. Lancet 2017;389:2304–2316.
- Griffiths CEM, Thaci D, Gerdes S, et al. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2017;176:928–938.
- Glintborg B, Sorensen IJ, Loft AG, et al. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis. 2017;76:1426–1431.
- Olech E. Biosimilars: rationale and current regulatory landscape. Semin Arthritis Rheum 2016;45:S1–S10.
- Are biosimilars the same as generic drugs? US Food and Drug Administration; 2017. Rockville, MD. [cited 2018 Sept 25]. Available from: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm580419.htm.
- CDER list of licensed biological products. US Food and Drug Administration; 2018. Rockville, MD. [cited 2018 Sept 25]. Available from: https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/UCM560162.pdf.
- Cote BR, Peterson EA. Impact of therapeutic switching in long-term care. Am J Manag Care. 2008;14:SP23–SP28.
- US Pain Foundation. Position statement – non-medical switching. 2019. Middletown, CT. [cited 2018 Oct 2]. Available from: https://uspainfoundation.org//advocacy/keyissues/nonmedical-switching/.
- Coalition of State Rheumatology Organizations. State advocacy: non-medical switching. 2019. Schaumburg, Illinois. [cited 2018 Oct 2]. Available from: http://csro.info/advocacy/state-advocacy/non-medical-switching.aspx.
- American Academy of Dermatology. Position statement on patient access to affordable treatments. 2017. Rosemont Illinois. [cited 2018 Sept 25]. Available from: https://www.aad.org/Forms/Policies/Uploads/PS/PS-Patient%20Access%20to%20Affordable%20Treatments.pdf.
- American Medical Association. Drug formularies and therapeutic interchange, Policy H-125.991. [cited 2018 Sept 25]. 2010. Chicago, Illinois. Available from: https://policysearch.ama-assn.org/policyfinder/detail/Drug%20Formularies%20and%20Therapeutic?uri=%2FAMADoc%2FHOD.xml-0-227.xml.
- Patient perspective on medication switching for non-medical reasons. Global Healthy Living Foundation; 2015. Location is Upper Nyack, NY. [cited 2018 Oct 4]. Available from: https://www.50statenetwork.org/wp-content/uploads/2015/04/GHLF-Switching-Stable-Patients-Survey_Summary.pdf.